Key Points
- Juan Jaen, President of Arcus Biosciences, sold 31,823 shares on Jan. 5 at an average price of $21.41 for a total of $681,330.43, reducing his ownership by 3.34% to 922,240 shares (about $19.7M).
- RCUS shares were trading up (opened $23.19) with a 12‑month range of $6.50–$26.40 and a market cap of ~$2.5B; the company reported a recent quarter EPS of ($1.27) and year‑over‑year revenue down ~45.8%, leaving a negative P/E of -6.74.
- Analysts are mixed but overall positive with a consensus rating of “Moderate Buy” and a $28.67 target, while institutional ownership is high at 92.89% and several large funds have recently increased positions.
Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) President Juan Jaen sold 31,823 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $21.41, for a total value of $681,330.43. Following the completion of the transaction, the president owned 922,240 shares in the company, valued at $19,745,158.40. The trade was a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Arcus Biosciences Trading Up 6.9%
RCUS stock opened at $23.19 on Thursday. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. Arcus Biosciences, Inc. has a twelve month low of $6.50 and a twelve month high of $26.40. The company has a market cap of $2.50 billion, a P/E ratio of -6.74 and a beta of 0.77. The business has a fifty day moving average of $22.55 and a 200-day moving average of $15.41.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping analysts' consensus estimates of ($1.33) by $0.06. The firm had revenue of $26.00 million during the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company's revenue was down 45.8% on a year-over-year basis. During the same period last year, the company earned ($1.00) earnings per share. As a group, equities research analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcus Biosciences in a research note on Wednesday, October 8th. The Goldman Sachs Group raised their price target on Arcus Biosciences from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Thursday, October 30th. Wells Fargo & Company lifted their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Monday, October 20th. Morgan Stanley reissued an "equal weight" rating and issued a $20.00 target price (down previously from $23.00) on shares of Arcus Biosciences in a research note on Thursday. Finally, Wedbush set a $35.00 target price on Arcus Biosciences and gave the stock an "outperform" rating in a report on Wednesday, October 29th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Arcus Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.67.
Get Our Latest Research Report on Arcus Biosciences
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Arcus Biosciences by 1.1% during the third quarter. Vanguard Group Inc. now owns 6,629,453 shares of the company's stock worth $90,161,000 after purchasing an additional 73,210 shares during the period. Woodline Partners LP increased its stake in Arcus Biosciences by 45.5% during the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company's stock worth $40,249,000 after purchasing an additional 1,603,367 shares in the last quarter. Geode Capital Management LLC raised its holdings in Arcus Biosciences by 14.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company's stock worth $12,995,000 after buying an additional 207,097 shares during the period. Bank of America Corp DE raised its holdings in Arcus Biosciences by 173.5% during the 3rd quarter. Bank of America Corp DE now owns 1,360,781 shares of the company's stock worth $18,507,000 after buying an additional 863,162 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of Arcus Biosciences by 35.3% in the third quarter. Wellington Management Group LLP now owns 1,266,289 shares of the company's stock valued at $17,222,000 after buying an additional 330,268 shares during the period. 92.89% of the stock is currently owned by institutional investors.
Arcus Biosciences Company Profile
(
Get Free Report)
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company's research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.
The company's lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
